Total Payments
$73,932
2024 Payments
$12,869
Companies
19
Transactions
211
Payment Breakdown by Category
Consulting$59,924 (81.1%)
Other$5,714 (7.7%)
Food & Beverage$4,198 (5.7%)
Travel$2,210 (3.0%)
Research$1,865 (2.5%)
Education$21.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $59,924 | 15 | 81.1% |
| Food and Beverage | $4,198 | 165 | 5.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,104 | 8 | 5.6% |
| Travel and Lodging | $2,210 | 9 | 3.0% |
| Unspecified | $1,865 | 12 | 2.5% |
| Grant | $1,610 | 1 | 2.2% |
| Education | $21.74 | 1 | 0.0% |
Payments by Type
General
$72,067
199 transactions
Research
$1,865
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $46,305 | 53 | $0 (2024) |
| ViiV Healthcare Company | $7,876 | 37 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,307 | 37 | $0 (2024) |
| Theratechnologies Inc. | $5,709 | 8 | $0 (2023) |
| Genentech, Inc. | $2,993 | 1 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $1,610 | 1 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $1,000 | 4 | $0 (2020) |
| Janssen Biotech, Inc. | $250.97 | 16 | $0 (2020) |
| Shionogi Inc | $186.02 | 16 | $0 (2024) |
| Melinta Therapeutics, Inc. | $165.83 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,869 | 42 | Gilead Sciences, Inc. ($9,257) |
| 2023 | $16,785 | 14 | Gilead Sciences, Inc. ($8,506) |
| 2022 | $145.66 | 2 | Gilead Sciences, Inc. ($126.75) |
| 2021 | $9,110 | 2 | Gilead Sciences, Inc. ($7,500) |
| 2020 | $3,328 | 7 | Merck Sharp & Dohme Corporation ($3,029) |
| 2019 | $9,036 | 44 | Gilead Sciences, Inc. ($8,350) |
| 2018 | $11,996 | 46 | Gilead Sciences, Inc. ($9,643) |
| 2017 | $10,663 | 54 | Merck Sharp & Dohme Corporation ($3,813) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/06/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: ANTIBIOTIC | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.84 | General |
| 11/21/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $31.92 | General |
| Category: Infectious Diseases | ||||||
| 11/06/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/01/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $10.79 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/18/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,992.50 | General |
| 10/08/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: ANTIBIOTIC | ||||||
| 10/08/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $0.23 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/07/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $30.09 | General |
| Category: Infectious Diseases | ||||||
| 10/02/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: ANTIBIOTIC | ||||||
| 10/01/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: HIV | ||||||
| 09/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $33.95 | General |
| Category: HIV | ||||||
| 09/19/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/09/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: ANTIBIOTIC | ||||||
| 09/06/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/04/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/07/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/03/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/21/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $1.77 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/20/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/12/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $1,624 | 7 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $240.44 | 5 |
About Dr. Eric Daar, M.D
Dr. Eric Daar, M.D is a Infectious Disease healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336119676.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Daar, M.D has received a total of $73,932 in payments from pharmaceutical and medical device companies, with $12,869 received in 2024. These payments were reported across 211 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($59,924).
Ad
Practice Information
- Specialty Infectious Disease
- Location Torrance, CA
- Active Since 01/26/2006
- Last Updated 10/19/2012
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1336119676
Products in Payments
- MK-1439 (Drug) $3,797
- TROGARZO (Drug) $2,500
- ZERBAXA (Drug) $232.96
- PREZCOBIX (Drug) $214.05
- DOVATO (Drug) $188.65
- Fetroja (Drug) $186.02
- TRIUMEQ (Drug) $155.31
- TEFLARO (Drug) $139.70
- DIFICID (Drug) $116.91
- Vabomere (Drug) $98.92
- PREVYMIS (Drug) $82.38
- NUZYRA (Drug) $81.97
- VIBATIV (Drug) $70.85
- Cresemba (Drug) $62.01
- Baxdela (Drug) $51.36
- Xerava (Drug) $45.31
- ISENTRESS (Drug) $42.98
- FFRct (Device) $40.00
- JULUCA (Drug) $36.81
- Genvoya (Drug) $35.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Torrance
James Mckinnell, M.d, M.D
Infectious Disease — Payments: $643,481
Infectious Disease $643,481
Mr. Behzad Noorian, Md, MD
Infectious Disease — Payments: $121,149
Infectious Disease $121,149
Brad Spellberg, M.d, M.D
Infectious Disease — Payments: $56,183
Infectious Disease $56,183
Loren Miller, M.d, M.D
Infectious Disease — Payments: $22,180
Infectious Disease $22,180
Mallory Witt, M.d, M.D
Infectious Disease — Payments: $7,542
Infectious Disease $7,542
Scott Filler, M.d, M.D
Infectious Disease — Payments: $7,250
Infectious Disease $7,250